Horizon Pharma plc
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$21.6M
Doctors Paid
25,219
Transactions
113,293
2018 Total
$10.8M
Payment Breakdown by Category
Research$10.3M (47.6%)
Food & Beverage$2.1M (9.7%)
Travel$944,042 (4.4%)
Consulting$426,409 (2.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $10.3M | 249 | 47.6% |
| Honoraria | $7.8M | 3,250 | 36.3% |
| Food and Beverage | $2.1M | 105,839 | 9.7% |
| Travel and Lodging | $944,042 | 3,197 | 4.4% |
| Consulting Fee | $426,409 | 66 | 2.0% |
| Space rental or facility fees (teaching hospital only) | $6,600 | 7 | 0.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $5,000 | 1 | 0.0% |
| Education | $2,634 | 684 | 0.0% |
Payments by Type
General
$11.3M
113,044 transactions
Research
$10.3M
249 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| TRASTUZUMAB AND PERTUZUMAB IN PATIENTS WITH HER-2 POSITIVE BREAST | $1.2M | 0 | 2 |
| TEPRO 301 | $1.0M | 0 | 9 |
| A PHASE 1, OPEN-LABEL, PARALLEL-GROUP, SINGLE DOSE STUDY TO EVALUATE THE PHARMACOKINETICS OF PROCYSBI CYSTEAMINE BITARTRATE IN SUBJECTS W ITH NORMAL AND IMPAIRED RENAL FUNCTION | $843,613 | 0 | 1 |
| MULTICENTER, SAFETY AND EFFICACY, OPEN-LABEL EXTENSION STUDY OF ACTIMMUNEINTERFERON -1B IN CHILDREN AND YOUNG ADULTS WITH FRIEDREICH'S ATAXIA | $777,455 | 0 | 4 |
| RECIPE | $392,181 | 0 | 3 |
| COMPARATIVE, RANDOMIZED, SINGLE-DOSE, 3-WAY CROSSOVER BIOEQUIVALENCE STUDY OF BUPHENYL SODIUM PHENYLBUTYRATE 500 MG TABLETS AND TWO NEW FORMULATIONS FOLLOWING ORAL ADMINISTRATION IN HEALTHY ADULT SUBJECTS UNDER FASTING CONDITIONS | $388,929 | 0 | 1 |
| THRIVE | $340,731 | 0 | 35 |
| CANCER | $329,342 | 0 | 20 |
| EFFECT OF INF ON INNATE CELLS EFFECTS OF ACTIMMUNE ON IN VIVO GENE EXPRESSION BIOLOGICAL ACTIVITY MARKERS FUNCTIONAL ACTIVITY OF MYELOID CELL | $300,000 | 0 | 1 |
| A LONG-TERM OPEN-LABEL EXTENSION STUDY OF RP103-MITO-001 TO ASSESS THE SAFETY, TOLERABILITY AND EFFICACY OF CYSTEAMINE BITARTRATE DELAYED-RELEASE CAPSULES RP103 FOR TREATMENT OF CHILDREN WITH INHERITED MITOCHONDRIAL DISEASE | $288,585 | 0 | 4 |
| ECONS PHASE 2A STUDY OF INTERFERON GAMMA-1B FOR THE TREATMENT OF AUTOSOMAL DOMINANT TYPE 2 OSTEOPETROSIS | $275,685 | 0 | 1 |
| HZNP-ACT-IIT-008 | $250,000 | 0 | 1 |
| HPN-100-021 | $247,612 | 0 | 5 |
| HZNP-KRY-IIT-001 | $219,341 | 0 | 8 |
| RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, EFFICACY, SAFETY | $185,082 | 0 | 4 |
| HNZP-PRE-IIT-004 | $177,253 | 0 | 12 |
| OBSERVATIONAL STUDY OF THE USE OF KRYSTEXXA PEGLOTICASE IN ADULT HYPERURICEMIC PATIENTS WITH GOUT REFRACTORY TO CONVENTIONAL THERAPY | $159,749 | 0 | 54 |
| HZNP-ACT-IIT-005 | $152,143 | 0 | 1 |
| 2705 NCI2013-01779 | $151,402 | 0 | 1 |
| HZNP-RAV-IIT-003 | $150,000 | 0 | 1 |
| LONG-TERM SAFETY EXTENSION STUDY OF ACTIMMUNE INTERFERON -1B IN CHILDREN AND YOUNG ADULTS WITH FRIEDREICHS ATAXIA | $142,643 | 0 | 4 |
| POLGREEN OPEN-LABEL PHASE 12 STUDY WITH A SINGLE ARM OF INTERFERON GAMMA-1B TREATMENT OF OSTEOPETROSIS | $141,896 | 0 | 2 |
| MULTICENTER SAFETY AND EFFICACY OPEN-LABEL EXTENSION STUDY EVALUATING TEPROTUMUMAB HZN-001 TREATMENT IN SUBJECTS WITH ACTIVE THYROID EYE DISEASE | $141,028 | 0 | 5 |
| HZNP-ACT-IIT-009 | $127,947 | 0 | 1 |
| HPN-100-009 | $125,668 | 0 | 2 |
| HZNP-PRO-IIT-005 | $121,347 | 0 | 2 |
| A MULTICENTER, DOUBLE-MASKED, PLACEBO-CONTROLLED, EFFICACY AND SAFETY STUDY OF AN INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR IGF-1RANTAGONIST ANTIBODY FULLY HUMAN, IN PATIENTS WITH ACTIVE THYROID EYE DISEASE | $118,957 | 0 | 5 |
| A PHASE I-II STUDY OF INTERFERON-GAMMA PLUS WEEKLY PACLITAXEL | $114,030 | 0 | 2 |
| A LONG-TERM OPEN-LABEL, SAFETY AND SUPERIOR EFFECTIVENESS STUDY OF CYSTEAMINE BITARTRATE DELAYED-RELEASE CAPSULES RP103 IN PATIENTS WITH CYSTINOSIS | $105,654 | 0 | 1 |
| THE ROLE OF IFN SUPPLEMENTATION IN T CELL EFFECTOR FUNCTION IN PATIENTS WITH CHRONIC GRANULOMATOUS DISEASE | $95,009 | 0 | 1 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2018 |
|---|---|---|---|---|
| Sanjay Chabra, D.o, D.O | Rheumatology | El Paso, TX | $332,693 | $0 |
| Gordon Lam, Md, MD | Rheumatology | Charlotte, NC | $275,171 | $0 |
| David Peura, M.d, M.D | Gastroenterology | Charlottesville, VA | $254,103 | $0 |
| Christopher Parker, Do, DO | Rheumatology | West Lake Hills, TX | $250,548 | $0 |
| Dr. Byron Cryer, M.d, M.D | Gastroenterology | Dallas, TX | $250,534 | $0 |
| Lee Simon, M.d, M.D | Rheumatology | Boston, MA | $222,089 | $0 |
| Edward Brettholz, Md, MD | Gastroenterology | New York, NY | $188,540 | $0 |
| Dr. John Cozzarelli, Dpm, DPM | Foot & Ankle Surgery | Belleville, NJ | $149,543 | $0 |
| Dr. John Botson, M.d., Rph, M.D., RPH | Rheumatology | Anchorage, AK | $147,491 | $0 |
| Korey Ullrich, M.d, M.D | Rheumatology | Boca Raton, FL | $139,022 | $0 |
| Dr. Anthony Anderson, Md, MD | Diagnostic Ultrasound | Greensboro, NC | $138,611 | $0 |
| Orrin Troum, Md, MD | Rheumatology | Santa Monica, CA | $132,223 | $0 |
| Dr. Mona Amin, D.o, D.O | Rheumatology | Glendale, AZ | $126,578 | $0 |
| Dr. Jeff Peterson, Md, MD | Rheumatology | Bothell, WA | $124,676 | $0 |
| Harry Hill, Md, MD | Pediatrics | Salt Lake City, UT | $119,166 | $0 |
| John Kolnik, D.o, D.O | Specialist | Haddon Heights, NJ | $112,497 | $0 |
| Dr. Naveen Reddy, Md, MD | Internal Medicine | Jupiter, FL | $111,747 | $0 |
| James Mossell, D.o, D.O | Rheumatology | Tifton, GA | $110,515 | $0 |
| Amar Majjhoo, Md, MD | Rheumatology | Saint Clair Shores, MI | $110,097 | $0 |
| Sanjay Godhwani, Md, MD | Internal Medicine | Wading River, NY | $104,679 | $0 |
| Allan Morton, D.o, D.O | Rheumatology | Warren, MI | $104,589 | $0 |
| David Mandel, M.d, M.D | Rheumatology | Mayfield Village, OH | $98,766 | $0 |
| Dr. Richard Haddad, Md, MD | Specialist | Red Bank, NJ | $89,578 | $0 |
| Scott Neville, Dpm, DPM | Foot & Ankle Surgery | Mooresville, IN | $87,777 | $0 |
| Dr. Arthur Mabaquiao, M.d, M.D | Rheumatology | San Diego, CA | $87,516 | $0 |
Ad
Top Products
- KRYSTEXXA $6.4M
- ACTIMMUNE $4.4M
Associated Products (10)
- ACTIMMUNE $6.7M
- RAYOS $4.7M
- PROCYSBI $3.7M
- PRIMARY CARE - DISEASE STATE $1.5M
- TEPRO $1.2M
- BUPHENYL $392,254
- QUINSAIR $182,044
- TEPROTUMUMAB $174,877
- VIMOVO $149,709
- NO_PRODUCT $124,316
Payment Categories
- Food & Beverage $2.1M
- Consulting $426,409
- Travel & Lodging $944,042
- Research $10.3M
About Horizon Pharma plc
Horizon Pharma plc has made $21.6M in payments to 25,219 healthcare providers, recorded across 113,293 transactions in the CMS Open Payments database. In 2018, the company paid $10.8M. The top product by payment volume is KRYSTEXXA ($6.4M).
Payments were distributed across 180 medical specialties. The top specialty by payment amount is Rheumatology ($5.5M to 1,911 doctors).
Payment categories include: Food & Beverage ($2.1M), Consulting ($426,409), Research ($10.3M), Travel & Lodging ($944,042).
Horizon Pharma plc is associated with 10 products in the CMS Open Payments database, including ACTIMMUNE, RAYOS, and PROCYSBI.